FindTrial
Sign In

mFOLFOX6 regimen

DRUG10 trials

Sponsors

Accelerated Community Oncology Research Network, Peking Union Medical College Hospital, Seoul National University Bundang Hospital, Gilead Sciences, Qilu Pharmaceutical Co., Ltd.

Conditions

Advanced Colorectal CancerAdvanced Solid TumorsCRCColorectal CancerColorectal NeoplasmsEffects of ChemotherapyGastric CancerGastric Cancer Stage IV

Phase 1

A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
TerminatedNCT00779311
Accelerated Community Oncology Research NetworkMetastatic Colorectal Cancer
Start: 2008-10-31End: 2011-03-31Updated: 2011-11-02
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6
CompletedNCT03618758
Seoul National University Bundang HospitalGastric Cancer Stage IV, Intraperitoneal Paclitaxel, mFOLFOX6 +1
Start: 2018-12-24End: 2023-12-02Updated: 2023-12-05
Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors
TerminatedNCT03954704
Gilead SciencesAdvanced Solid Tumors
Start: 2019-06-03End: 2021-04-15Updated: 2023-11-21
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RecruitingNCT06445062
Revolution Medicines, Inc.Colorectal Cancer, CRC, Gastrointestinal Cancer +3
Start: 2024-05-24End: 2027-07-15Target: 1130Updated: 2026-04-01

Phase 2

FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer
NCT02226380
Peking Union Medical College HospitalEffects of Chemotherapy, Gastric Cancer, Surgery
Start: 2013-10-31Target: 75Updated: 2014-08-27
Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer
NCT04310176
National Cancer Institute, NaplesRas-mutated Metastatic Colorectal Cancer
Start: 2019-05-24End: 2024-11-30Target: 200Updated: 2023-11-13
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
NCT05193292
Fudan UniversityColorectal Neoplasms, Intestinal Neoplasms
Start: 2022-01-31End: 2025-01-31Target: 77Updated: 2022-01-14
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
RecruitingNCT06908031
Sixth Affiliated Hospital, Sun Yat-sen UniversityHigh-Risk Cancer, MSS, Rectal Adenocarcinoma
Start: 2025-04-02End: 2027-04-01Target: 49Updated: 2025-05-14

Phase 3

QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety
NCT04233151
Qilu Pharmaceutical Co., Ltd.Metastatic Colorectal Cancer
Start: 2020-01-20End: 2025-07-30Target: 590Updated: 2023-05-26
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Active, not recruitingNCT04793958
Mirati Therapeutics Inc.Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Start: 2021-06-24End: 2026-01-30Updated: 2025-02-11

Related Papers

Abstract A118: Daraxonrasib, a RAS(ON) multi-selective inhibitor, exhibits potent antitumor activity and combinatorial benefit with standard of care chemotherapy and with anti-PD-1 in preclinical models of KRAS G12R PDAC
Cancer Research2025-09-28
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
Journal of Medicinal Chemistry2025-03-0832 citations
Adagrasib (Ada) + cetuximab (Cetux) for <i>KRAS</i> <sup>G12C</sup> -mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.
Journal of Clinical Oncology2025-01-272 citations
QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.
Journal of Clinical Oncology2025-01-27
Peritoneal regression grading score (PRGS): first evidence for independent predictive and prognostic significance
Pleura and Peritoneum2023-05-1813 citations
Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer2023-02-0128 citations
Safety and efficacy of intraperitoneal paclitaxel plus systemic FOLFOX for gastric cancer with peritoneal metastasis: Phase I results.
Journal of Clinical Oncology2022-01-19
377 Characterization of peripheral biomarkers of GS-1423, a first in class bifunctional anti-CD73-TGFβ receptor II- trap molecule, in a phase 1 dose escalation study in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer2021-11-01
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocol
Therapeutic Advances in Medical Oncology2020-01-0116 citations
A phase II study of neoadjuvant chemotherapy with a modified FOLFOX6 regimen for locally advanced gastric cancer.
Journal of Clinical Oncology2016-02-01